Rockwell Medical (RMTI) Cost of Revenue (2010 - 2026)

Rockwell Medical (RMTI) has reported Cost of Revenue for 17 consecutive years, with $14.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 7.14% year-over-year to $14.5 million; the trailing twelve-month figure through Jun 2026 stood at $57.1 million (down 21.3% YoY), and the FY2025 full-year result was $57.6 million, down 31.48% from the prior year.
• Cost of Revenue climbed to $14.5 million in Q2 2026 per RMTI's latest filing, from $14.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $22.1 million in Q3 2024 and bottomed at $13.6 million in Q2 2025.
• Historically, Cost of Revenue has averaged $17.5 million across 5 years, with a median of $17.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue advanced 24.84% in 2024, then sank 38.15% in 2025.
• Over 5 years, Cost of Revenue stood at $17.0 million in 2022, then climbed by 13.26% to $19.2 million in 2023, then rose by 9.42% to $21.0 million in 2024, then plunged by 31.22% to $14.5 million in 2025, then grew by 0.48% to $14.5 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $14.5 million, $14.4 million, and $14.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.